StockData
Danaher Corp logo

Danaher Corp

DHRNYSEIndustrial Instruments For Measurement, Display, and ControlFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 26, 2026Last filing: 10-Q on Jul 21, 2026Score 12/3027% above fair value
$232.23−4.75 (-2.00%)

Close on Oct 30, 2026Market cap $163.25BP/E 41.2Yield –

Danaher Beckman Coulter (Diagnostics & Life Sciences) by Quarter

Beckman Coulter (Diagnostics & Life Sciences) — MAUDE Adverse Event Reports

QuarterlyAnnualMonthly

Danaher Beckman Coulter (Diagnostics & Life Sciences): 541 in Q3 2026, up 238.1% from a year earlier.

Latest, Q3 2026
541
Period ended Sep 30, 2026
Change on a year earlier
+238.1%
160 in Q3 2025
History
47 quarters
Since Q1 2015
Sources
1
U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE)

Where the Q3 2026 figure comes from

Source: U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗

Reported in U.S. FDA openFDA MAUDE Adverse Event API.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedBeckman Coulter (Diagnostics & Life Sciences) — MAUDE Adverse Event ReportsYear on yearSource
Q3 2026Sep 30, 2026541+238.1%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q2 2026Jun 30, 2026154-25.2%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q1 2026Mar 31, 2026187-8.8%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q4 2025Dec 31, 2025174+3.6%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q3 2025Sep 30, 2025160-27.9%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q2 2025Jun 30, 2025206+44.1%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q1 2025Mar 31, 2025205+21.3%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q4 2024Dec 31, 2024168+17.5%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q3 2024Sep 30, 2024222+49.0%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q2 2024Jun 30, 2024143-12.3%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q1 2024Mar 31, 2024169-11.1%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q4 2023Dec 31, 2023143-7.1%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q3 2023Sep 30, 2023149+6.4%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q2 2023Jun 30, 2023163+3.8%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q1 2023Mar 31, 2023190+6.1%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗
Q4 2022Dec 31, 2022154-34.2%U.S. FDA openFDA API (510(k), PMA, Recalls, Enforcement, MAUDE) ↗

Cite this data

StockData. (2026). Danaher Beckman Coulter (Diagnostics & Life Sciences), quarterly Q1 2015–Q3 2026 [Data set]. Compiled from Danaher SEC filings and investor materials. https://stockdatahq.com/stocks/dhr/kpis/ext-fda-maude-beckman-coulter

See every metric in the Danaher KPI table. Data updated Nov 2, 2026.